↓ Skip to main content

Dove Medical Press

Article Metrics

Epiregulin as a therapeutic target in non-small-cell lung cancer

Overview of attention for article published in Lung Cancer: Targets and Therapy, October 2015
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (51st percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
15 Mendeley
Title
Epiregulin as a therapeutic target in non-small-cell lung cancer
Published in
Lung Cancer: Targets and Therapy, October 2015
DOI 10.2147/lctt.s60427
Pubmed ID
Authors

Noriaki Sunaga, Kyoichi Kaira

Abstract

Epiregulin (EREG) belongs to the ErbB family of ligands. EREG binds to EGFR and ErbB4 receptor and stimulates homodimers of EGFR and ErbB4 in addition to all possible heterodimeric ErbB complexes, resulting in the activation of downstream signaling pathways. EREG is overexpressed in various human cancers and has been implicated in tumor progression and metastasis. Oncogenic activation of the MEK/ERK pathway plays a central role in the regulation of EREG expression. Non-small-cell lung cancers (NSCLCs) harboring KRAS, BRAF, or EGFR mutations overexpress EREG, and abrogation of such mutations or inhibition of MEK or ERK downregulates the expression of EREG. Elevated EREG expression in NSCLC is associated with aggressive tumor phenotypes and unfavorable prognosis, especially in oncogenic KRAS-driven lung adenocarcinomas. The finding that attenuation of EREG inhibits cell growth and induces apoptosis in KRAS-mutant and EREG-overexpressing NSCLC cell lines suggests that targeting EREG might be a treatment option for KRAS-mutant NSCLC, although further studies are necessary to elucidate its therapeutic value. These observations suggest that oncogenic mutations in the EGFR, KRAS, or BRAF genes induce EREG upregulation through the activation of MEK/ERK pathway in NSCLC cells, whereas overproduced EREG stimulates the EGFR/ErbB receptors and activates multiple downstream signaling pathways, leading to tumor progression and metastasis of these oncogene-driven NSCLCs. This paper reviews the current understanding of the oncogenic role of EREG and highlights its potential as a therapeutic target for NSCLC.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 15 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 15 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 5 33%
Researcher 3 20%
Student > Bachelor 3 20%
Unspecified 1 7%
Student > Doctoral Student 1 7%
Other 1 7%
Unknown 1 7%
Readers by discipline Count As %
Medicine and Dentistry 4 27%
Agricultural and Biological Sciences 4 27%
Biochemistry, Genetics and Molecular Biology 3 20%
Pharmacology, Toxicology and Pharmaceutical Science 1 7%
Immunology and Microbiology 1 7%
Other 1 7%
Unknown 1 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 October 2015.
All research outputs
#8,319,856
of 14,432,394 outputs
Outputs from Lung Cancer: Targets and Therapy
#1
of 1 outputs
Outputs of similar age
#113,689
of 253,484 outputs
Outputs of similar age from Lung Cancer: Targets and Therapy
#1
of 1 outputs
Altmetric has tracked 14,432,394 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1 research outputs from this source. They receive a mean Attention Score of 0.0. This one scored the same or higher as 0 of them.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 253,484 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them